27 May 2022
Appendix 3H
29 April 2022
Quarterly Cashflow and Activities Report
28 April 2022
Change in Substantial Holder
27 April 2022
Starpharma to present DEP® at Boston ADC summit
1 April 2022
Starpharma appoints Dr Jeff Davies and Appendix 3X
1 April 2022
VIRALEZE™ to relaunch in the UK
17 March 2022
Appendix 2A
4 March 2022
Response to media article
1 March 2022
SPL7013 in VIRALEZE™ virucidal against Omicron
24 February 2022
Dr Jeff Davies appointed as non-executive director
21 February 2022
Starpharma Interim Report and Half-Year Financial Results
4 February 2022
VIRALEZE™ Saudi Arabia Distribution - supplementary information
4 February 2022
Change in Substantial Holder
3 February 2022
VIRALEZE™ sales and distribution in Saudi Arabia and GCC
1 February 2022
Appendix 3H
1 February 2022
Appendix 2A
1 February 2022
Appendix 2A
28 January 2022
Quarterly Cashflow and Activities Report
20 January 2022
Starpharma receives $7.7M R&D tax incentive refund
23 December 2021
Appendix 3H

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.